Metastatic Chromophobe Renal Cell Carcinoma: Presence or Absence of Sarcomatoid Differentiation Determines Clinical Course and Treatment Outcomes
Yasser Ged(Memorial Sloan Kettering Cancer Center), Martin H. Voss(Memorial Sloan Kettering Cancer Center), Almedina Redzematovic(Memorial Sloan Kettering Cancer Center), Chung‐Han Lee(Memorial Sloan Kettering Cancer Center), Paul Russo(Memorial Sloan Kettering Cancer Center), Andrea Knežević(Memorial Sloan Kettering Cancer Center), Renzo G. DiNatale(Memorial Sloan Kettering Cancer Center), Ying‐Bei Chen(Memorial Sloan Kettering Cancer Center), Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Sujata Patil(Kettering University), Maria I. Carlo(Memorial Sloan Kettering Cancer Center), A. Ari Hakimi(Penn State Milton S. Hershey Medical Center), Jozefina Casuscelli(LMU Klinikum), Darren R. Feldman(Memorial Sloan Kettering Cancer Center)
Cited by 63
Related Papers
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k